莱茵生物
(002166)
| 流通市值：50.30亿 | | | 总市值：50.50亿 |
| 流通股本：7.39亿 | | | 总股本：7.42亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 873,376,148.72 | 446,871,087.43 | 2,043,836,317.7 | 1,272,155,817.35 |
| 营业总成本 | 813,239,614.59 | 401,670,515.61 | 1,858,906,809.19 | 1,186,425,574.15 |
| 其他经营收益 | | | | |
| 营业利润 | 80,299,530.11 | 51,611,457.2 | 204,966,827.63 | 106,582,077.92 |
| 利润总额 | 79,816,138.67 | 51,595,809.06 | 200,700,725.07 | 104,929,663.04 |
| 净利润 | 57,665,949.55 | 42,640,384.59 | 152,883,586.27 | 79,191,843.56 |
| 每股收益 | | | | |
| 其他综合收益 | -26,780,847.59 | -10,543,840.78 | -6,907,607.08 | -1,069,684.73 |
| 综合收益总额 | 30,885,101.96 | 32,096,543.81 | 145,975,979.19 | 78,122,158.83 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,471,725,308.48 | 2,768,035,071.14 | 2,991,206,272.19 | 2,570,216,019.08 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,337,783,184.56 | 2,358,360,565.87 | 2,390,839,707.55 | 2,414,856,218.71 |
| 资产总计 | 4,809,508,493.04 | 5,126,395,637.01 | 5,382,045,979.74 | 4,985,072,237.79 |
| 流动负债: | | | | |
| 流动负债合计 | 1,362,708,460.85 | 1,568,032,061.1 | 1,873,530,695.92 | 1,490,169,063.63 |
| 非流动负债: | | | | |
| 非流动负债合计 | 248,557,757.54 | 286,276,487.01 | 268,524,738.73 | 332,595,507.44 |
| 负债合计 | 1,611,266,218.39 | 1,854,308,548.11 | 2,142,055,434.65 | 1,822,764,571.07 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,113,463,787.03 | 3,188,307,531.1 | 3,156,334,837.7 | 3,076,548,372.75 |
| 股东权益合计 | 3,198,242,274.65 | 3,272,087,088.9 | 3,239,990,545.09 | 3,162,307,666.72 |
| 负债和股东权益合计 | 4,809,508,493.04 | 5,126,395,637.01 | 5,382,045,979.74 | 4,985,072,237.79 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,288,336,759.89 | 820,952,930.98 | 1,929,960,753.89 | 1,518,730,522.97 |
| 经营活动现金流出小计 | 856,384,301.44 | 508,082,737.77 | 1,769,752,655.09 | 1,172,272,820.74 |
| 经营活动产生的现金流量净额 | 431,952,458.45 | 312,870,193.21 | 160,208,098.8 | 346,457,702.23 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 300,903.49 | 289,924.18 | 8,575,943.08 | 5,538,573.33 |
| 投资活动现金流出小计 | 68,739,020.16 | 38,501,822.49 | 162,162,280.89 | 120,246,861.48 |
| 投资活动产生的现金流量净额 | -68,438,116.67 | -38,211,898.31 | -153,586,337.81 | -114,708,288.15 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 327,996,544 | 206,000,000 | 1,353,448,408.5 | 802,448,408.5 |
| 筹资活动现金流出小计 | 643,885,399.75 | 248,064,512.32 | 1,345,838,532.37 | 946,548,653.54 |
| 筹资活动产生的现金流量净额 | -315,888,855.75 | -42,064,512.32 | 7,609,876.13 | -144,100,245.04 |
| 汇率变动对现金及现金等价物的影响 | -2,750,456.68 | -2,144,401.33 | 1,150,099.23 | 1,492,697.06 |
| 现金及现金等价物净增加额 | 44,875,029.35 | 230,449,381.25 | 15,381,736.35 | 89,141,866.1 |
| 期末现金及现金等价物余额 | 110,026,172.05 | 295,600,523.95 | 65,151,142.7 | 138,911,272.45 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 44,875,029.35 | - | 15,381,736.35 | - |